All questionsPharmacology: Keytruda (pembrolizumab) in high-risk early-stage triple-negative breast cancer3 questions · 2 sourcesMechanismHow does KEYTRUDA work (mechanism of action)?“Pembrolizumab binds to the PD-1 receptor, blocking both immune-suppressing ligands, PD-L1 and PD-L2, from interacting with PD-1 to help restore T-cell response and immune response. Restoring active T-cell response could affect both normal healthy cells and tumor cells.” (opens the source at this quote in a new tab)CopyFlagPharmacokineticsWhat is the half-life of KEYTRUDA?“Pembrolizumab clearance (CV%) is approximately 23% lower [geometric mean, 195 mL/day (40%)] at steady state than that after the first dose [252 mL/day (37%)]; this decrease in clearance with time is not considered clinically important. The terminal half-life (t1/2) is 22 days (32%).” (opens the source at this quote in a new tab)CopyFlagComponentsWhat are the ingredients in KEYTRUDA?“Each vial contains 100 mg of pembrolizumab in 4 mL of solution. Each 1 mL of solution contains 25 mg of pembrolizumab and is formulated in: L-histidine (1.55 mg), polysorbate 80 (0.2 mg), sucrose (70 mg), and Water for Injection, USP.” (opens the source at this quote in a new tab)CopyFlag